AZD2066: Clinical Trials

8 completed, 2 terminated. 7 Phase 1, 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7
Phase 2	4	Completed 2, Terminated 2

Follow AZD2066: new trials by email Literature Review of AZD2066 trials Research Report on AZD2066

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder AZD2066, Placebo, Duloxetine - Major Depressive Disorder	Phase 2	Terminated	AstraZeneca	131	2010-05-01	2012-10-03
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity AZD2066, Placebo - Neuropathic Pain, Mechanical Hypersensitivity	Phase 2	Terminated	AstraZeneca	87	2009-08-01	2012-09-27
AZD2066 Cocktail Study AZD2066, Caffeine, Tolbutamide - Chronic Pain	Phase 1	Completed	AstraZeneca	15	2009-06-01	2009-10-27
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy AZD2066, Placebo - Pain, Diabetic Neuropathy	Phase 2	Completed	AstraZeneca	127	2009-02-01	2012-11-12
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066 AZD2066 - Pain	Phase 1	Completed	AstraZeneca	6	2009-01-01	2009-02-25
14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations AZD2066, Placebo - Reflux Episodes	Phase 1 / Phase 2	Completed	AstraZeneca	40	2008-12-01	2010-12-07
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects AZD2066, Placebo - Healthy	Phase 1	Completed	AstraZeneca	132	2008-09-01	2009-08-25
AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers AZD2066 - Healthy	Phase 1	Completed	AstraZeneca	20	2008-04-01	2010-12-10
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 AZD2066, radioligand [11C] AZ12713580 - Healthy	Phase 1	Completed	AstraZeneca	6	2008-04-01	2010-12-10
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects AZD2066, Placebo - Pain	Phase 1	Completed	AstraZeneca	110	2008-01-01	2010-12-10

Conditions studied

Pain (5)  ·  Agnosia (3)  ·  Chronic Pain (1)  ·  Depression (1)  ·  Depressive Disorder, Major (1)  ·  Diabetic Neuropathies (1)  ·  Gastroesophageal Reflux (1)  ·  Hyperalgesia (1)  ·  Neuralgia (1)

Sponsors

AstraZeneca (10)

Countries

United States (3)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Japan (1)  ·  Netherlands (1)

Top investigators

Biljana Lilja (3)  ·  Anders Neijber (1)  ·  Bo Fransson (1)  ·  Bo Fransson, MD (1)  ·  Brett Stacey (1)  ·  Charles E Argoff, MD (1)  ·  Eleanor Lisbon, MD, MPH (1)  ·  Emeline Ramos, MD (1)  ·  Guy E Boeckxstaens, MD, PhD (1)  ·  Heather Wray, MB, ChB, FFPM (1)  ·  Ivan Eggens, MD (1)  ·  Lars Stahle, MD, PhD (1)  ·  Lora McGill (1)  ·  Marie Sundin (1)